Bioventix delivered a very credible set of interims given the impact of COVID-19 on the broader IVD market. Revenues rose 1% resulting in an adjusted pre-tax profit and adjusted EPS falling 7% and 9% to £3.9m and 61.5p, respectively. An interim dividend of 43p was declared (+19%) with net cash at period end of £5.8m. Vitamin D antibody sales/royalties were c.£2.3m (up c.4% on H2 FY 2020), with troponin more than doubling to c.£0.3m and the balance of its portfolio up c.8%. The macro outlook for ....
29 Mar 2021
Bioventix - Interim results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bioventix - Interim results
Bioventix Plc (BVXP:LON) | 4,450 0 0.0% | Mkt Cap: 232.3m
- Published:
29 Mar 2021 -
Author:
Mark Brewer | Cavendish Research -
Pages:
14
Bioventix delivered a very credible set of interims given the impact of COVID-19 on the broader IVD market. Revenues rose 1% resulting in an adjusted pre-tax profit and adjusted EPS falling 7% and 9% to £3.9m and 61.5p, respectively. An interim dividend of 43p was declared (+19%) with net cash at period end of £5.8m. Vitamin D antibody sales/royalties were c.£2.3m (up c.4% on H2 FY 2020), with troponin more than doubling to c.£0.3m and the balance of its portfolio up c.8%. The macro outlook for ....